Peter Nell, Mammoth Biosciences CBO

Jen­nifer Doud­na spin­out inks a Mam­moth CRISPR deal with Ver­tex worth near­ly $700M

When a com­pa­ny gets its start in gene edit­ing pi­o­neer Jen­nifer Doud­na’s lab, it’s bound to make head­lines. But three years in, the fan­fare still …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.